AIM ImmunoTech is trading 7.8% down at $0.21 after no clear company-specific catalyst emerged overnight.
- The latest official release, dated September 9, 2026, discussed Ampligen and continued DURIPANC clinical progress, not negative news.
- Major U.S. futures were modestly higher on September 11, so broader market weakness does not clearly explain the decline.
- The move may reflect low-liquidity trading or undisclosed selling pressure.